Journal of Allergy and Clinical Immunology-In Practice最新文献

英文中文

Polycystic ovary syndrome and the risk of asthma in reproductive-age women: Insights from 2 real-world large cohorts 多囊卵巢综合征与育龄妇女的哮喘风险：来自两个真实世界大型队列的启示。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.009

Battoul Fakhry MD , Amy Attaway MD , Hyun Jo Kim MS , Zaid Yaqoob MD , Sadeer G. Al-Kindi MD, PhD , Celine Chedraoui MD , Joelle Sleiman MD , Joe G. Zein MD, PhD

引用次数: 0

Atopic Dermatitis (Eczema) Guidelines 2023: Highlights 特应性皮炎（湿疹）指南 2023》：亮点。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.052

Anna De Benedetto MD , Mark Boguniewicz MD , Peck Y. Ong MD , Derek K. Chu MD, PhD , Lynda C. Schneider MD

Atopic dermatitis is a common chronic inflammatory skin disorder, with a complex pathogenesis. It is characterized by eczematous skin lesions, pruritus, and recurrent skin infections and has a negative impact on patients’ and caregivers’ quality of life. The American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Atopic Dermatitis Guideline Panel recently released updated AD guidelines. This guideline focuses on addressing clinical questions using trustworthy guideline development standards, including mitigating the potential influence of financial and nonfinancial conflicts of interest, and Grading of Recommendations Assessment, Development, and Evaluation methodology. A multidisciplinary panel used systematic reviews and meta-analyses to inform specific recommendations addressing optimal use of topical treatments, dilute bleach bath, dietary avoidance/elimination, allergen immunotherapy, and systemic treatments. The comprehensive recommendations, emphasizing the third principle of evidence-based medicine—that evidence alone is never enough, and that patient values and preferences must be carefully considered when determining optimal treatments for patients and populations—provide a framework to support clinicians in selecting an optimal treatment plan for each patient. This review provides an overview of the guideline and discusses how those recommendations relate to current practice.

特应性皮炎（AD）是最常见的慢性炎症性皮肤病之一，发病机制复杂。特应性皮炎以皮肤湿疹、瘙痒和反复皮肤感染为特征，对患者（和护理人员）的生活质量有负面影响。美国过敏、哮喘和免疫学学会（AAAAI）/美国过敏、哮喘和免疫学学院（ACAAI）特应性皮炎联合工作组（JTF）指南小组最近发布了最新的特应性皮炎指南。该指南的重点是采用值得信赖的指南制定标准（包括减轻经济和非经济利益冲突的潜在影响）和 GRADE 方法解决临床问题。一个多学科小组利用系统综述和荟萃分析，针对以下方面提出了具体建议：(1) 局部治疗；(2) 稀释漂白浴；(3) 避免/消除饮食；(4) 过敏原免疫疗法；(5) 全身治疗。这些全面的建议强调了循证医学的第三条原则--仅有证据是远远不够的；在为患者和人群确定最佳治疗方法时，必须仔细考虑患者的价值观和偏好--为临床医生为每位患者选择最佳治疗方案提供了一个框架。本综述概述了该指南，并讨论了这些建议与当前实践的关系。

{"title":"Atopic Dermatitis (Eczema) Guidelines 2023: Highlights","authors":"Anna De Benedetto MD , Mark Boguniewicz MD , Peck Y. Ong MD , Derek K. Chu MD, PhD , Lynda C. Schneider MD","doi":"10.1016/j.jaip.2024.08.052","DOIUrl":"10.1016/j.jaip.2024.08.052","url":null,"abstract":"<div><div>Atopic dermatitis is a common chronic inflammatory skin disorder, with a complex pathogenesis. It is characterized by eczematous skin lesions, pruritus, and recurrent skin infections and has a negative impact on patients’ and caregivers’ quality of life. The American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Atopic Dermatitis Guideline Panel recently released updated AD guidelines. This guideline focuses on addressing clinical questions using trustworthy guideline development standards, including mitigating the potential influence of financial and nonfinancial conflicts of interest, and Grading of Recommendations Assessment, Development, and Evaluation methodology. A multidisciplinary panel used systematic reviews and meta-analyses to inform specific recommendations addressing optimal use of topical treatments, dilute bleach bath, dietary avoidance/elimination, allergen immunotherapy, and systemic treatments. The comprehensive recommendations, emphasizing the third principle of evidence-based medicine—that evidence alone is never enough, and that patient values and preferences must be carefully considered when determining optimal treatments for patients and populations—provide a framework to support clinicians in selecting an optimal treatment plan for each patient. This review provides an overview of the guideline and discusses how those recommendations relate to current practice.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"12 11","pages":"Pages 2955-2965"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining the Utility of Penicillin Allergy Clinical Decision Rules: How Low Will You Go? 检验青霉素过敏临床决策规则的实用性：您的要求有多低？

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.053

Sara Vogrin MBiostat , Kimberly G. Blumenthal MD, MSc , Jason A. Trubiano MBBS, PhD

引用次数: 0

To DRESS, or Not to DRESS, That Is the Question 穿还是不穿，这是个问题。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.048

Munir Pirmohamed MBChB (Hons), PhD

引用次数: 0

Characterization and Incidence of Sunflower Seed Allergy in a Pediatric Allergy Clinic 儿科过敏门诊中葵花籽过敏的特征和发病率。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.07.029

Elsa R. Treffeisen MD, MPH , Claire Mepyans BA , Ellen R. Conroy MD , Heather J. Baer ScD , David N. Williams PhD , Kathryn A. Williams MS , Lynda C. Schneider MD

Background

Sunflower seeds are a popular allergen-free peanut alternative.

Objective

To describe sunflower seed allergy incidence and characteristics.

Methods

We conducted a retrospective cohort study of patients with sunflower seed allergy from 1995 to 2021 in a pediatric allergy clinic. We described demographic characteristics, testing results, atopic comorbidities, and reaction histories of patients with sunflower seed allergy and calculated the annual cumulative incidence of the allergy. Logistic regression was used to estimate the increase in odds of sunflower seed allergy diagnosis for each year from 1995 to 2021.

Results

From 1995 to 2021, we identified 235 patients with sunflower seed allergy. Among patients with sunflower seed allergy, the median age at diagnosis was 3.9 years. More than three-quarters of patients had another atopic condition. Half of the reactions consisted of mild urticaria or rash, and a quarter met criteria for anaphylaxis. The cumulative incidence ranged from 0% (1995-1999, 2001-2004, and 2006) to 0.38% (2021). From 1995 to 2021, the odds of sunflower seed allergy diagnosis increased annually by 21% (odds ratio, 1.21; 95% CI, 1.17-1.25).

Conclusions

In our single-center cohort of children with sunflower seed allergy, most children were diagnosed in early childhood, had high rates of comorbid atopic conditions, and had high rates of cutaneous reactions to sunflower seed products. Moreover, in our cohort, incidence of sunflower seed allergy increased.

背景：葵花籽是一种广受欢迎的不含过敏原的花生替代品：葵花籽是一种广受欢迎的不含过敏原的花生替代品：描述葵花籽过敏的发病率和特征：我们对一家儿科过敏诊所 1995 年至 2021 年期间的葵花籽过敏患者进行了一项回顾性队列研究。我们描述了葵花籽过敏患者的人口统计学特征、检测结果、特应性合并症和反应史，并计算了过敏的年累计发病率。我们使用逻辑回归法估算了 1995 年至 2021 年间每年确诊葵花籽过敏几率的增长情况：从 1995 年到 2021 年，我们共发现 235 名葵花籽过敏患者。在葵花籽过敏患者中，确诊年龄的中位数为 3.9 岁。超过四分之三的患者患有其他特应性疾病。半数反应为轻度荨麻疹或皮疹，四分之一符合过敏性休克的标准。累计发病率从 0%（1995-1999 年、2001-2004 年和 2006 年）到 0.38%（2021 年）不等。从 1995 年到 2021 年，诊断出葵花籽过敏的几率每年增加 21%（OR 1.21，95% CI：1.17-1.25）：在我们的单中心葵花籽过敏儿童队列中，大多数儿童在幼儿期就被确诊，合并特应性疾病的比例很高，对葵花籽产品的皮肤反应发生率也很高。此外，在我们的队列中，葵花籽过敏的发病率呈上升趋势。

{"title":"Characterization and Incidence of Sunflower Seed Allergy in a Pediatric Allergy Clinic","authors":"Elsa R. Treffeisen MD, MPH , Claire Mepyans BA , Ellen R. Conroy MD , Heather J. Baer ScD , David N. Williams PhD , Kathryn A. Williams MS , Lynda C. Schneider MD","doi":"10.1016/j.jaip.2024.07.029","DOIUrl":"10.1016/j.jaip.2024.07.029","url":null,"abstract":"<div><h3>Background</h3><div>Sunflower seeds are a popular allergen-free peanut alternative.</div></div><div><h3>Objective</h3><div>To describe sunflower seed allergy incidence and characteristics.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of patients with sunflower seed allergy from 1995 to 2021 in a pediatric allergy clinic. We described demographic characteristics, testing results, atopic comorbidities, and reaction histories of patients with sunflower seed allergy and calculated the annual cumulative incidence of the allergy. Logistic regression was used to estimate the increase in odds of sunflower seed allergy diagnosis for each year from 1995 to 2021.</div></div><div><h3>Results</h3><div>From 1995 to 2021, we identified 235 patients with sunflower seed allergy. Among patients with sunflower seed allergy, the median age at diagnosis was 3.9 years. More than three-quarters of patients had another atopic condition. Half of the reactions consisted of mild urticaria or rash, and a quarter met criteria for anaphylaxis. The cumulative incidence ranged from 0% (1995-1999, 2001-2004, and 2006) to 0.38% (2021). From 1995 to 2021, the odds of sunflower seed allergy diagnosis increased annually by 21% (odds ratio, 1.21; 95% CI, 1.17-1.25).</div></div><div><h3>Conclusions</h3><div>In our single-center cohort of children with sunflower seed allergy, most children were diagnosed in early childhood, had high rates of comorbid atopic conditions, and had high rates of cutaneous reactions to sunflower seed products. Moreover, in our cohort, incidence of sunflower seed allergy increased.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"12 11","pages":"Pages 3081-3088.e6"},"PeriodicalIF":8.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Belgian IgE study: Staphylococcus aureus toxins in adult severe asthma 比利时 IgE（BEIgE）研究：成人重症哮喘中的金黄色葡萄球菌毒素。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.016

Florence Schleich MD, PhD , Eléonore Maury PhD , Claus Bachert MD, PhD , Mieke Jansen PhD , Sandra Gurdain MD , Jan Van Schoor MD, PhD

引用次数: 0

Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi 生物制剂对非甾体抗炎药物引起的胃食管反流病的疗效：从鼻子到支气管的联合气道

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.10.003

引用次数: 0

Transient Serpentine Supravenous Erythema During Rapid Drug Desensitization 快速药物脱敏过程中的短暂蛇麻素静脉上红斑

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.031

Malina C. Patel MD , Dan Costin MD , Beth McLellan MD , Sara DiFalco RN , Jessica Oh MD

引用次数: 0

Consultation for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Clinical Presentation, Diagnostic Workup, and Treatment Options 慢性鼻炎伴鼻息肉和哮喘的会诊：临床表现、诊断工作和治疗方案。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.07.019

Anju T. Peters MD , Bruce K. Tan MD , Whitney W. Stevens MD, PhD

Chronic rhinosinusitis (CRS) is characterized by chronic inflammation of the sinonasal mucosa, affects over 12% of the US population, and costs over $20 billion annually. CRS can be divided into 2 major phenotypes based on whether nasal polyps are present (chronic rhinosinusitis with nasal polyps [CRSwNP]) or absent (chronic rhinosinusitis without nasal polyps). This grand rounds review will discuss the clinical approach to patients with CRSwNP, including typical presentations, workup, and currently available treatment options. Tools that physicians can use to assess subjective sinonasal symptoms, as well as objective measures of disease, will be reviewed. Additional focus will be on recognizing clinical comorbidities commonly associated with CRSwNP, including asthma, bronchiectasis, allergic rhinitis, and nonsteroidal anti-inflammatory drug–exacerbated respiratory disease. Clinical outcomes can be improved by providing a comprehensive approach to evaluating (and managing) patients with CRSwNP.

慢性鼻炎（CRS）以鼻窦粘膜慢性炎症为特征，影响着 12% 以上的美国人口，每年造成的损失超过 200 亿美元。根据鼻息肉是否存在（CRSwNP）或不存在（CRSsNP），CRS 可分为两种主要表型。本次大查房回顾将讨论 CRSwNP 患者的临床治疗方法，包括典型表现、检查方法和目前可用的治疗方案。还将回顾医生可用于评估主观鼻窦症状的工具以及疾病的客观指标。此外，还将重点介绍与 CRSwNP 常见的临床合并症，包括哮喘、支气管扩张、过敏性鼻炎和非甾体类抗炎药加重的呼吸道疾病（NSAID-ERD）。通过对 CRSwNP 患者进行全面的评估（和管理），可以改善临床疗效。

引用次数: 0

Induction of sustained remission and reversal of pathologic transcriptome achieved with tezepelumab in an adolescent with eosinophilic esophagitis 使用替塞单抗诱导嗜酸性粒细胞食管炎青少年病情持续缓解并逆转病理转录组。

IF 8.2 1区医学 Q1 ALLERGY

Journal of Allergy and Clinical Immunology-In Practice

Pub Date : 2024-11-01 DOI: 10.1016/j.jaip.2024.08.013

Colby S. Sharlin MD , Margaret H. Collins MD , Scott M. Bolton MD , Garrett A. Osswald BS , Ghassan S. Safadi MD , Kara L. Kliewer RD, PhD , Marc E. Rothenberg MD, PhD , Tetsuo Shoda MD, PhD , Vincent A. Mukkada MD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Allergy and Clinical Immunology-In Practice

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀